ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, J
Right arrow Articles by Britton, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, J
Right arrow Articles by Britton, J
Eur Respir J 1997; 10: 2225-2229
Copyright © ERS Journals Ltd 1997

Clinical Trial

Investigation of the effect of short-term change in dietary magnesium intake in asthma

J Hill, A Micklewright, S Lewis, and J Britton

Epidemiological evidence suggests that a low dietary intake of magnesium is associated with impaired lung function, bronchial hyperreactivity and wheezing. This study was designed to investigate whether short-term alterations of dietary magnesium intake have an effect on the clinical control of asthma. In a randomized, double-blind, placebo-controlled, cross-over study, 17 asthmatic subjects adhered to a low magnesium diet for two periods of 3 weeks, preceded and separated by a 1 week run-in/wash-out, in which they took either placebo or magnesium (400 mg x day(-1)) tablet supplementation. Forced expiratory volume in one second (FEV1) and the provocative dose of methacholine required to cause a 20% fall in FEV1 from baseline (PD20,FEV1) were measured at the beginning and end of each treatment period, and variation in peak expiratory flow (PEF) rate, bronchodilator use and symptom scores recorded throughout. Asthma symptom scores were significantly lower during the magnesium treatment period, the median (95% confidence interval) difference from placebo being 3.8 (0.5-7.0) symptom points per 7 days (p=0.02). However, there was no significant improvement in FEV1, PD20,FEV1, log amplitude percentage mean PEF variation or bronchodilator use during magnesium supplementation. A high magnesium intake was associated with improvement in symptom scores, though not in objective measures of airflow or airway reactivity, in these stable asthmatic subjects.


This article has been cited by other articles:


Home page
 J. Nutr.Home page
E. S. Ford and A. H. Mokdad
Dietary Magnesium Intake in a National Sample of U.S. Adults
J. Nutr., September 1, 2003; 133(9): 2879 - 2882.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
F. D. Gilliland, K. T. Berhane, Y.-F. Li, D. H. Kim, and H. G. Margolis
Dietary Magnesium, Potassium, Sodium, and Children's Lung Function
Am. J. Epidemiol., January 15, 2002; 155(2): 125 - 131.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K G Tantisira and S T Weiss
Complex interactions in complex traits: obesity and asthma
Thorax, September 1, 2001; 56(90002): ii64 - 74.
[Full Text] [PDF]

Home page
 ChestHome page
O. S. B. Alamoudi
Electrolyte Disturbances in Patients With Chronic, Stable Asthma : Effect of Therapy
Chest, August 1, 2001; 120(2): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. Stenius-Aarniala, T. Poussa, J. Kvarnström, E.-L. Grönlund, M. Ylikahri, and P. Mustajoki
Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study
BMJ, March 25, 2000; 320(7238): 827 - 832.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.